Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Epoetin Hospira MDV vs SDV in Healthy Subjects
NCT03398473Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jan 2018
- Primary completion
- Apr 2018
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Epoetin alfa RB in anemia (2 arms), sponsored by Pfizer. Primary endpoints: Maximum serum concentration, Area under the serum concentration-time profile from time 0 to the last quantifiable concentration and 1 more. Started Jan 2018; status: completed.
02
Drugs
Epoetin alfa RB
03
Conditions
anemia
Beyond the preview
Go deeper on NCT03398473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03398473.